References
  1. Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE. PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics 2014; 24:73-79.
  2. Poirier A, Pormtan R, Cascais AC, Bader U, Wlater I, Ullah M, Funk C. The need for human breast cancer resistance protein substrate nad inhibition evaluation in drug discovery and development: why, when and how? Drug Metab Dispos 2014; 42:1466-1477.
  3. Dalla Vecchia Genvigir F, Cerda A, Dominguez Crespo Hirata T, Hirata MH, Dominguez Crespo Hirata R. Mycophenolic acid pharmacogenomics in kidney transplantation. J Transl Genet Genom 2020; 4:320-355.
  4. Miura M, Kagaya H, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit 2008; 30:559-564.
  5. Pearl J. Causality: models, reasoning and inference. 2nd ed. Cambridge, Cambridge University press, 2009.
  6. VanderWeele TJ. Principles of confounder selection. Eur J Epidemiol. 2019; 34:211-219.
  7. VenderWeele TJ, Rothman KJ, Lash TL. Confounding and confounders. In: Lash TL, VanderWeele TJ, Haneuse S, Rothman KJ (eds) Modern epidemiology, 4th edn. Wolters Kluwver, Philadephia, 2021, pp 610-667.
  8. Textor J, van der Zander B, Gilthorpe MS, Liskiewicz M, Elliot GTH. Robust causal inference using directed acyclic graphs: the R package “dagitty”. Int J Epidemiol 2016; 45:1887-1894.
  9. Gupta A, Dai Y, Vethanayagam RR, Herber MF, Thummel KE, Unadkat JD et al. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 2006; 58:374-383.
  10. Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 2013; 23:563-585.
  11. Fohner AE, Brackman DJ, Giacomini KM, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for ABCG2. Pharmacogenet Genomics 2017; 27:420-427.
  12. Bakhsheshian J, Hall MD, Robey RW, Herrmann MA, Chen JQ, Bates SE, Gottesman MM. Overlapping substrate and inhibitor specificity of human and murine ABCG2. Drug Metab Dispos 2013; 41:1805-1812.
  13. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46:13-58.
  14. Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 2011; 21:152-161.
  15. Organic anion transporting polypeptide (OATP). Available at: Organic anion transporting polypeptide (OATP) (straighthealthcare.com), Accessed August 25, 2022.
  16. Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet 2013; 52:751-762.
  17. Božina N, Lalić Z, Nađ Škegro S, Borić-Bilušić A, Božina T, Kaštelan Ž, Trkulja V. Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients’ and donors’ ABCC2 gene variants and their interactions. Eur J Clin Pharmacol 2017; 73:1129-1140.
  18. Hu DG, Meech R, Lu L, McKinnon RA, Mackenzie PI. Polymorphisms and haplotypes of the UDP-glucuronosyltransferase 2B7 gene promoter. Drug Metab Dispos 2014; 42:854-862.
  19. Strassburg CP, Barut A, Obermayer-Straub P, Li Q, Nguyen N, Tukey RH, Manns MP. Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by differently expressed UDP-glucuronosyltransferase: UGT2B7. J Hepatol 2001; 34: 865-872.
  20. Tron C, Memaitre F, Cerstuyft C, Petitcollin A, Verdier MC, Bellissant E. Pharmacogenetics of membrane transporters of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2019; 58:593-613.
  21. Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M et al. Mycophenolate, clinical pharmacokinetics, formulations and methods for assessing exposure. Transplant Rev 2011; 25:47-57.